Telix Pharmaceuticals Signs licence and distribution agreement for Illuccix
- Telix Pharmaceuticals (TLX) signs a licence and distribution agreement with Isologic Innovative Pharmaceuticals for its investigational prostate cancer imaging agent Illuccix
- Under the agreement, Isologic will be the commercial distributor of Illuccix in Canada for four years, subject to achieving annual minimum sales
- Isologic’s President Dr André Gagnon said PSMA PET imaging is a new technology that could transform the way prostate cancer is initially staged and managed
- According to the Canadian Cancer Society, prostate cancer is the most common cause of cancer
- TLX are up 1.96 per cent and trading at $4.17 per share at market close
